Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Ā 
Ā 

Bausch Health Companies Inc. (NYSETSX: BHC) (theĀ "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exchange Offers, the "Offers") to amend certain provisions of the indentures (the "Proposed Amendments") with respect to the respective applicable series of Existing Senior Notes. The terms and conditions of the offers and consent solicitations are described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated August 30, 2022 (the "Exchange Offer Memorandum").

Ā 

The Exchange Offers expired at 11:59 p.m. , New York City time, on September 27, 2022 (the "Expiration Time"). As reported by D.F. King & Co., Inc., the exchange agent and information agent for the Offers, as of the Expiration Time, an aggregate principal amount of $5,594,432,000 of Existing Senior Notes had been validly tendered (and not validly withdrawn) in the Offers, as set forth in the table below.

Ā 
Ā 
Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā 
Ā 

Ā Ā  Title of Existing Senior Notes Ā Ā 

Ā 
Ā 

Ā Ā  CUSIP Number (1) Ā Ā 

Ā 

Ā Ā  (Rule 144A/Reg S) Ā Ā 

Ā 
Ā 

Ā Ā  Principal Amount
Outstanding
Ā 
Ā 

Ā 
Ā 

Ā Ā  Tender Cap Ā Ā 

Ā 
Ā 

Ā Ā  Acceptance
Priority Level
Ā  (2)
Ā 

Ā 
Ā 

Ā Ā  Principal Amount
Tendered
Ā 
Ā 

Ā 
Ā 

Ā  9.00% Senior Notes due 2025 Ā 

Ā 
Ā 

Ā  91911KAP7 /
C94143AM3
Ā 

Ā 
Ā 

Ā  $ 1,500,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  1 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  540,662,000 Ā 

Ā 
Ā 

Ā  9.25% Senior Notes due 2026 (3) Ā 

Ā 
Ā 

Ā  91911XAV6 /
U9098VAN2
Ā 

Ā 
Ā 

Ā  $ 1,500,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  2 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  752,398,000 Ā 

Ā 
Ā 

Ā  8.50% Senior Notes due 2027 Ā  (3)

Ā 
Ā 

Ā  91911XAW4 /
U9098VAP7
Ā 

Ā 
Ā 

Ā  $ 1,750,000,000 Ā 

Ā 
Ā 

Ā  $500,000,000 ( Ā  4 )

Ā 
Ā 

Ā  3 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā  Ā Ā 500,000,000 Ā 

Ā 
Ā 

Ā  5.25% Senior Notes due 2031 Ā 

Ā 
Ā 

Ā  071734AL1 /
C07885AG8
Ā 

Ā 
Ā 

Ā  $Ā Ā Ā  909,188,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  4 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā  Ā Ā Ā 336,499,000 Ā 

Ā 
Ā 

Ā  5.25% Senior Notes due 2030 Ā 

Ā 
Ā 

Ā  071734AJ6 /
C07885AE3
Ā 

Ā 
Ā 

Ā  $ 1,201,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  5 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  331,952,000 Ā 

Ā 
Ā 

Ā  5.00% Senior Notes due 2029 Ā 

Ā 
Ā 

Ā  071734AM9 /
C07885AH6
Ā 

Ā 
Ā 

Ā  $Ā Ā Ā  834,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  6 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  371,067,000 Ā 

Ā 
Ā 

Ā  5.00% Senior Notes due 2028 Ā 

Ā 
Ā 

Ā  071734AH0 /
C07885AD5
Ā 

Ā 
Ā 

Ā  $ 1,176,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  7 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  710,075,000 Ā 

Ā 
Ā 

Ā  6.25% Senior Notes due 2029 Ā 

Ā 
Ā 

Ā  071734AK3 /
C07885AF0
Ā 

Ā 
Ā 

Ā  $ 1,406,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  8 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  540,099,000 Ā 

Ā 
Ā 

Ā  7.25% Senior Notes due 2029 Ā 

Ā 
Ā 

Ā  071734AF4 /
C07885AC7
Ā 

Ā 
Ā 

Ā  $Ā Ā Ā  745,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  9 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  372,967,000 Ā 

Ā 
Ā 

Ā  7.00% Senior Notes due 2028 Ā 

Ā 
Ā 

Ā  071734AD9 /
C07885AB9
Ā 

Ā 
Ā 

Ā  $Ā Ā  748,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  10 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  539,614,000 Ā 

Ā 
Ā 

Ā  8.50% Senior Notes due 2027 Ā  (3)

Ā 
Ā 

Ā  91911XAW4 /
U9098VAP7
Ā 

Ā 
Ā 

Ā  $ 1,750,000,000 Ā 

Ā 
Ā 

Ā  N/A Ā 

Ā 
Ā 

Ā  11 Ā 

Ā 
Ā 

Ā  $Ā Ā Ā Ā Ā Ā  599,099,000 Ā 

Ā 
Ā 
Ā 

Ā 

Ā 

Ā 

Ā 
Ā 
Ā Ā Ā Ā Ā Ā Ā Ā 
Ā 

Ā  (1) Ā 

Ā 
Ā 

Ā  No representation is made as to the correctness or accuracy of the CUSIP numbers listed in this press release or printed on the Existing Senior Notes. They are provided solely for convenience. Ā 

Ā 
Ā 

Ā  (2) Ā 

Ā 
Ā 

Ā  Existing Senior Notes accepted for exchange on the settlement date will be accepted in accordance with their Acceptance Priority Levels set forth herein (with "1" being the highest Acceptance Priority Level and "11" being the lowest Acceptance Priority Level). The Offerors will only accept for exchange Existing Senior Notes up to an aggregate principal amount that will not cause the aggregate principal amount of New Secured Notes issued pursuant to the Offers to exceed the Maximum New Secured Notes Amount. Ā 

Ā 
Ā 

Ā  (3) Ā 

Ā 
Ā 

Ā  Bausch Health Americas, Inc. ("BHA") is the issuer and the Company is a guarantor of such series of Existing Senior Notes. Ā 

Ā 
Ā 

Ā  (4) Ā 

Ā 
Ā 

Ā  No more than $500.0 million aggregate principal amount of the 8.50% Senior Notes due 2027 (the "Level 3 Tender Cap") will be purchased at level "3" in the Exchange Offers. Ā 

Ā 
Ā 
Ā 

Ā 

Ā 

Subject to the terms and conditions set forth in the Exchange Offer Memorandum, upon settlement of the Exchange Offers, which is currently expected to occur on September 30, 2022 (the "Settlement Date"), there will beĀ approximately $3,125 million of New Secured Notes issued in the Offers, consisting of approximately (i) $1,774 million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the "New First Lien Notes"), (ii) $352 million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the "New Second Lien Notes" and, together with the New First Lien Notes, the "New BHC Secured Notes"), in each case, to be issued by the Company, and (iii) $999 million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the "Intermediate Holdco Secured Notes" and, together with the New BHC Secured Notes, the "New Secured Notes") to be issued by 1375209 B .C. Ltd. (the "Holdco Issuer" and, together with the Company, the "Offerors"), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. All Eligible Holders (as defined in the Exchange Offer Memorandum) of Existing Senior Notes accepted for exchange pursuant to the Offers on the Settlement Date will also be paid a cash amount equal to accrued and unpaid interest for such series of Existing Senior Notes from the last interest payment date for such series of Existing Senior Notes to, but not including, the Settlement Date.

Ā 

In addition to the previously announced receipt of the requisite number of consents to adopt the Proposed Amendments with respect to the (i) 9.25% Senior Notes due 2026, (ii) 8.50% Senior Notes due 2027, (iii) 5.00% Senior Notes due 2028 and (iv) 7.00% Senior Notes due 2028 and the execution of the supplemental indentures related thereto, as of the Expiration Time, the Company also received the requisite number of consents to adopt the Proposed Amendments with respect to the 7.25% Senior Notes due 2029. Accordingly, pursuant to the terms set forth in the Exchange Offer Memorandum, the Company intends to enter into a supplemental indenture with the trustee for the 7.25% Senior Notes due 2029 to effectuate the applicable Proposed Amendments. Each supplemental indenture will become operative upon the settlement date of the Offers.

Ā 

The New Secured Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and may not be offered or sold in the United States , except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The New Secured Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any issuance of New Secured Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the New Secured Notes in the United States and shall not constitute an offer, solicitation or sale of the New Secured Notes in any jurisdiction where such offering or sale would be unlawful. There shall not be any sale of the New Secured Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Ā 
Ā  About Bausch Health Companies Inc. Ā 
Ā 

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our approximately 88.7% ownership of Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Ā 
Ā  Forward-Looking Statements Ā 
Ā 

This news release may contain forward-looking statements about the future performance of the Company, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Company's overall business, including those more fully described in the Company's most recent annual report on Form 10-K and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian securities administrators, which factors are incorporated herein by reference.

Ā 
Ā 
Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā 
Ā 

Ā Ā  Investor Contact: Ā Ā 

Ā 
Ā 

Ā Ā Ā  Media Contacts: Ā Ā Ā 

Ā 
Ā 
Ā 
Ā 

Ā  Christina Cheng Ā 

Ā 
Ā 

Ā  Kevin Wiggins Ā 

Ā 
Ā 

Ā Ā Ā  ir@bauschhealth.com Ā Ā Ā 

Ā 
Ā 

Ā Ā Ā  corporate.communications@bauschhealth.com Ā Ā Ā 

Ā 
Ā 

Ā  (514) 856-3855 Ā 

Ā 
Ā 

Ā  848) 541-3785 Ā 

Ā 
Ā 

Ā  (877) 281-6642 (toll free) Ā 

Ā 
Ā 
Ā 
Ā 

Ā 

Ā 
Ā 

Ā Ā Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)Ā 

Ā 
Ā 

Ā 

Ā 
Ā 
Ā 

Ā Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch-health-announces-final-results-and-expiration-of-exchange-offers-and-consent-solicitations-301635421.html Ā 

Ā 

SOURCE Bausch Health Companies Inc.

Ā 
Ā 

News Provided by PR Newswire via QuoteMedia

BHC:CA,BHC
The Conversation (0)
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Ā 

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C

Ā 

"We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1-phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC," said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health. "The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc

With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on whether a rehearing will be granted within the next three months.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for TechnegasĀ®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of TechnegasĀ® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

Ɨ